Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 0%
Hold 83%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharma is facing a downgrade to Hold due to concerns about future growth and a lack of near-term catalysts. This is largely due to the unexpected underperformance of Baqsimi in 1Q26, with a significant decrease in sales and expected price erosion. While the company is taking actions to address these issues, a return to prior levels of sales growth for Baqsimi is unlikely, leading to a flat-to-low single digit growth estimate for 2026.

Bears say

Amphastar Pharma is facing challenges in launching new products, with lower than expected revenue and earnings in the first quarter of 2026 due to pricing pressure and competition in the generics business. The company also has a number of complex generic and brand products in its pipeline, but the timeline for when these products may contribute to revenue is uncertain. As a result, there is a lack of visibility into the company's growth potential, leading to a negative outlook on the stock. Additionally, Amphastar's dependence on pipeline development for future success poses a high degree of risk.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 0% recommend Buy, 83% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.